Trials / Recruiting
RecruitingNCT07483385
Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- The General Hospital of Western Theater Command · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Conditions
- Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation
- Hematologic Disorders
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lusutrombopag | Lusutrombopag at a starting dose of 3 mg once daily. Treatment will continue for 2 weeks until CR is achieved, or treatment is discontinued after 14 days of continuous therapy, or when the discontinuation criteria are met. After the trial period plus 14 days, patients will be observed to determine if continued medication or regimen changes are necessary. |
Timeline
- Start date
- 2026-01-13
- Primary completion
- 2027-01-28
- Completion
- 2028-01-28
- First posted
- 2026-03-19
- Last updated
- 2026-03-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07483385. Inclusion in this directory is not an endorsement.